The latest price target for Sunshine Biopharma (NASDAQ:SBFM) was reported by Aegis Capital on August 7, 2023. The analyst firm set a price target for $2.60 expecting SBFM to rise to within 12 months (a possible 749.67% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Sunshine Biopharma (NASDAQ:SBFM) was provided by Aegis Capital, and Sunshine Biopharma initiated their buy rating.

There is no last upgrade for Sunshine Biopharma

There is no last downgrade for Sunshine Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sunshine Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sunshine Biopharma was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

While ratings are subjective and will change, the latest Sunshine Biopharma (SBFM) rating was a initiated with a price target of $0.00 to $2.60. The current price Sunshine Biopharma (SBFM) is trading at is $0.31, which is within the analyst’s predicted range.